Alzamend Neuro annual return on equity
2021
2022
2023
2024
2025
2026
Alzamend Neuro Return on Equity (ROE) Growth & History (ALZN)
Alzamend Neuro's return on equity was −373.18% for fiscal 2026.
View full Alzamend Neuro company overviewAlzamend Neuro annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-04-30 | −373.18% | +283.99 pp |
| 2025 | 2025-04-30 | −657.17% | +3751.14 pp |
| 2024 | 2024-04-30 | −4,408.31% | −4226.83 pp |
| 2023 | 2023-04-30 | −181.47% | −20.56 pp |
| 2022 | 2022-04-30 | −160.92% | +195.14 pp |
| 2021 | 2021-04-30 | −356.06% | — |
Alzamend Neuro quarterly return on equity
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2026 | 2026-04-30 | −195.69% | −164.97 pp |
| Q3 2026 | 2026-01-31 | −66.90% | −38.04 pp |
| Q2 2026 | 2025-10-31 | −20.60% | +86.59 pp |
| Q1 2026 | 2025-07-31 | −58.05% | — |
| Q4 2025 | 2025-04-30 | −30.72% | — |
| Q3 2025 | 2025-01-31 | −28.86% | — |
| Q2 2025 | 2024-10-31 | −107.18% | — |
| Q1 2024 | 2023-07-31 | −240.59% | −215.83 pp |
| Q4 2023 | 2023-04-30 | −74.24% | −43.67 pp |
| Q3 2023 | 2023-01-31 | −74.08% | −53.49 pp |
| Q2 2023 | 2022-10-31 | −31.15% | −5.77 pp |
| Q1 2023 | 2022-07-31 | −24.76% | +1.97 pp |
| Q4 2022 | 2022-04-30 | −30.57% | +58.10 pp |
| Q3 2022 | 2022-01-31 | −20.59% | — |
| Q2 2022 | 2021-10-31 | −25.38% | — |
| Q1 2022 | 2021-07-31 | −26.73% | — |
| Q4 2021 | 2021-04-30 | −88.68% | — |
Alzamend Neuro return on equity trends
Over the last five fiscal years, Alzamend Neuro's return on equity decreased from −356.06% to −373.18%, a change of −17.12 percentage points. The latest reported quarter, Q4 2026, shows −195.69%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alzamend Neuro source filings ↗